SEELQ — Seelos Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Brief: Seelos Therapeutics Doses First Patients In An Ethnobridging Study With SLS-002
Brief: Seelos Therapeutics Announces Data Demonstrating Downregulation Of Alpha Synuclein In An In Vivo Gene Therapy Study Of SLS-004 Utilizing CRISPR-dCas9 In Parkinson's Disease
Brief: Seelos Therapeutics Gets Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
Brief: Seelos Therapeutics Doses First Patient In A Registrational Phase Ii/Iii Study Of Sls-005 In Spinocerebellar Ataxia
Brief: Seelos Therapeutics Announces Participation Of Acadia Healthcare In The Registration Directed Study Of SLS-002
Brief: Seelos Therapeutics Inc - Received Letter From Nasdaq Notifying Co It Has Regained Full Compliance With Nasdaq Listing Rule
Seelos Therapeutics jumps on grant for Parkinson's gene therapy
Brief: Seelos Therapeutics Receives Research And Development Grant From Michael J. Fox Foundation For Parkinson's Research For SLS-004
Brief: Seelos Doses First Patient In Open Label Basket Study Of SLS-005 In ALS In Australia
Brief: Seelos Therapeutics Announces Data Demonstrating Significant Downregulation Of Mrna And Reduction Of Alpha Synuclein In An In Vitro Gene Therapy Study
Brief: Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
Brief: Seelos Therapeutics Says Entered Into Open Market Sale Agreement With Jefferies
Brief: Seelos Therapeutics - On April 22, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq - Filing
Brief: Seelos Therapeutics Amends SLS-002 Agreement
U.S. STOCKS ON THE MOVE-Dick's Sporting, Dish Network, Bumble
Seelos Therapeutics rises on nod to begin neurodisease drug study in Australia
Brief: Seelos Therapeutics Receives Acknowledgement Letter Of A Clinical Trial Notification From Australian Government
Brief: Seelos Therapeutics Announces Dosing Of The First Participants In Trial Of SLS-005
Sage's 'underwhelming' depression drug data a boost for Seelos - B.Riley